openPR Logo
Press release

Deadline on April 8th in Lawsuit for Investors in Biogen Inc. (NASDAQ: BIIB) coming up

03-22-2022 11:24 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A Deadline is coming up on April 8, 2022 in the lawsuit for certain investors in Biogen Inc. (NASDAQ: BIIB) and Biogen Inc. (NASDA

A Deadline is coming up on April 8, 2022 in the lawsuit for certain investors in Biogen Inc. (NASDAQ: BIIB) and Biogen Inc. (NASDA

A deadline is coming up on April 8, 2022 in the lawsuit filed for certain investors of Biogen Inc. (NASDAQ: BIIB) over alleged securities laws violations by Biogen Inc.

Investors who purchased shares of Biogen Inc. (NASDAQ: BIIB) have certain options and there are strict and short deadlines running. Deadline: April 8, 2022. NASDAQ: BIIB stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint filed in the U.S. District Court for the District of Massachusetts the plaintiff alleges on behalf of purchasers of Biogen Inc. (NASDAQ: BIIB) common shares between June 7, 2021 and January 11, 2022, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between June 7, 2021 and January 11, 2022, the Defendants made materially false and/or misleading statements and/or failed to disclose that there was a significant, undisclosed lobbying campaign between Biogen and the Food and Drug Administration ("FDA") that was instrumental in the decision to file and approve Aduhelm, a drug being developed to treat Alzheimer's disease, that the Phase III ENGAGE study demonstrated that Aduhelm failed to achieve a clinical benefit to Alzheimer's patients, that ENGAGE was a failed study from which Biogen concluded not to seek FDA approval for Aduhelm in 2019, and that defendants misled investors as to the way in which approval was achieved, that the clinical data did not support a clinical benefit by taking Aduhelm and that side-effects were dangerous and serious.

Those who purchased shares of Biogen Inc. (NASDAQ: BIIB) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Deadline on April 8th in Lawsuit for Investors in Biogen Inc. (NASDAQ: BIIB) coming up here

News-ID: 2584199 • Views:

More Releases from Shareholders Foundation

Investigation announced for Investors in shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR) over possible Violations of Securities Laws
Investigation announced for Investors in shares of Lifecore Biomedical, Inc. (NA …
An investigation was announced for investors of Lifecore Biomedical, Inc. (NASDAQ: LFCR) shares over potential securities laws violations by Lifecore Biomedical, Inc. Investors who purchased shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Lifecore Biomedical, Inc. regarding its business, its prospects and
Investigation announced for Investors in shares of Designer Brands Inc. (NYSE: DBI) over potential Wrongdoing by certain directors
Investigation announced for Investors in shares of Designer Brands Inc. (NYSE: D …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Designer Brands Inc. Investors who purchased shares of Designer Brands Inc. (NYSE: DBI) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Designer Brands Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders. Columbus,
Lawsuit Alert: Investors who lost money with shares of Innoviz Technologies Ltd. (NASDAQ: INVZ) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with shares of Innoviz Technologies Ltd. …
An investor, who purchased shares of Innoviz Technologies Ltd. (NASDAQ: INVZ), filed a lawsuit over alleged violations of Federal Securities Laws by Innoviz Technologies Ltd. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Innoviz Technologies Ltd. (NASDAQ: INVZ) have certain options and for certain investors are short and strict deadlines running. Deadline: May 14, 2024. NASDAQ: INVZ investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com
Lawsuit filed for Investors who lost money with shares of iRobot Corporation (NASDAQ: IRBT)
Lawsuit filed for Investors who lost money with shares of iRobot Corporation (NA …
An investor, who purchased shares of iRobot Corporation (NASDAQ: IRBT), filed a lawsuit over alleged violations of Federal Securities Laws by iRobot Corporation in connection with certain allegedly false and misleading statements. Investors who purchased shares of iRobot Corporation (NASDAQ: IRBT) have certain options and for certain investors are short and strict deadlines running. Deadline: May 7, 2024. NASDAQ: IRBT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)

All 5 Releases


More Releases for Biogen

Europe Anaerobic Digestion Market Analysis Focusing on Top Key Players Biogen, C …
Market Study Report adds Europe Anaerobic Digestion market report that gives meticulous investigation of current scenario of the market size, share, demand, growth, trends, companies active in the industry and forecasts for the coming years. The Netherlands in 2016, accounted for over 4% annual capacity share across the Europe anaerobic digestion market. Cost competitive deployment of AD systems when compared to landfill and incineration based plants will appreciably drive the industry
Global Multiple Sclerosis (MS) Market 2018 Key Players: Bayer Healthcare, Merck …
Multiple Sclerosis (MS) Market: WiseGuyReports.com adds “Multiple Sclerosis (MS) Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting 2027” reports tits database. Executive Summary DelveInsight’s Multiple Sclerosis (MS) - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical &forecasted epidemiology as well as the market trends of Multiple Sclerosis (MS) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan. The Report
Europe anaerobic digestion Market Detail Analysis focusing on Key Players BTS Bi …
The Europe anaerobic digestion market is projected to witness a commendable growth rate over the approaching years, on account of stringent government regulations to treat residues and waste with minimal ecological impact and burgeoning initiatives to uphold energy security. Apart from the factors mentioned above, other factors propelling the market include high operational performance, low emission rate, and cost-effectiveness of anaerobic digestion over other energy sources. Moreover, swift urbanization coupled
Europe anaerobic digestion Market Brief Analysis by Top Key Players BTS Biogas, …
The newly released research at Market Study Report titled “2017-2024 Europe anaerobic digestion Market Report” provides data, information, brief analysis, company profiles, statistics for past years and forecasts for next few years. The Netherlands in 2016, accounted for over 4% annual capacity share across the Europe anaerobic digestion market. Cost competitive deployment of AD systems when compared to landfill and incineration based plants will appreciably drive the industry growth. Additionally,
Recombinant Factor VIII Market Is Booming Worldwide | Pfizer, Biogen, Octapharma
A new independent 123 page research with title 'Global Recombinant Factor VIII Market Report 2018' guarantees you will remain better informed than your competition. The study covers geographic analysis that includes regions like North America, Europe, Asia, South America, Other Country and important players/vendors such as Shire (Baxter), Bayer, CSL etc. With n-number of tables and figures examining the Global Recombinant Factor VIII Market, the research gives you a visual,
Clarke Energy, Biogen Profiled in Europe Anaerobic Digestion Market 2024 Report …
MarketStudyReport.com Adds New Europe Anaerobic Digestion Market 2017 – 2024 research report providing information and data By Feedstock, By End Use, Industry Analysis, Regional Outlook, Growth Potential, Trends, Competitive Market Share & Forecast spreading across 105 Pages with table and figures in it. Europe anaerobic digestion market will exceed USD 8 billion by 2024. Large scale deployment of sustainable energy across industrial establishments favored by rapid industrialization will augment the Europe